Publications 1999

 

Flandre Ph, Saïdi Y. Estimating the proportion of treatment effect explained by a surrogate marker. Stat. Med. 1999, 18 : 107-9.

O’Quigley J, Flandre Ph, Reiner E.Large sample theory for Schemper’s measures of explained variation in the cox regression model.
J. R. Statist. Soc. D, 42 : 53-62.

Flandre Ph on behalf of the Delta Coordinating Committee.Patients with HIV-1 RNA below 1000 copies after 48 weeks on treatment (AZT+ddI or AZT+ddC) : baseline characteristics and pronostic. AIDS 1999, 13 : 430-31.Lien PubMed

Delta Coordinating Committee and Virology Group.HIV-1 RNA response to antiretroviral treatment in 1280 participants in the Delta Trial : an extended virology study.
AIDS 1999, 13 : 57-65.Lien PubMed

Delta Coordinating Committee and Virology Group. An evaluation of HIV RNA and CD4 cell count as surrogates for clinical outcome.
AIDS 1999, 13 : 565-573.Lien PubMed

The European Mode of Delivery Collaboration.Elective caesarean-section versus vaginal delivery in prevention of vertical HIV-1 transmission : a randomised clinical trial.
The Lancet 1999, 1035-39.Lien PubMed

Aboulker JP, Dormont J. Les inhibiteurs nucléosidiques de la transcriptase inverse : les pionniers de la thérapique anti-VIH..
Virologie mars 1999, vol.3.

Levy Y, Capitant C, Houhou S, Carriere I, Viard JP, Goujard C, Gastaut JA, Oksenhendler E, Boumsell L, Gomard E, Rabian C, Weiss L, Guillet JG, Delfraissy JF, Aboulker JP, Seligmann M, and the ANRS 048 study group. Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection : a randomised controlled trial. The Lancet 1999, 353 : 1923-29. Lien PubMed

Raffi F, Franck J, Pelloux H, Derouin F, Reliquet V, Ambroise-thomas P, Aboulker JP, Leport C, Dumon H.Specific Anti-Toxoplasmic IgG Antibody Immunoblot Profiles in Patients with AIDS-Associated Toxoplasma Encephalitis.
Diagn Microbiol Infect Dis 1999, 34 : 51-56.Lien PubMed

Salmon-Ceron D, Fillet AM, Aboulker JP, Gerard L, Houhou N, Carrier I, Ostinelli J, Vildé JL, Brun-Vezinet F, Leport C, and the ANRS 023. Effect of a 14-Days Course of Foscarnet on Cytomegalovirus (CMV) blood Markers in a Randomized Study of Human Immunodeficiency virus infected Patients with Persistent CMV Viremia.
Clinical Infectious Diseases 1999, 28 : 901-5. Lien PubMed

Masquelier B, Descamps D, Carrière I, Ferchal F, Collin G, Denayrolles M, Ruffault A, Chanzy B, Izopet J, Buffet-Janvresse C, Schmitt MP, Race E, Fleury HJA, Aboulker JP, Yeni P, Brun-Vezinet F.Zidovudine resensitization and dual HIV-1 resistance to zidovudine and lamivudine in the Delta lamivudine roll-over study.
Antiviral Therapy 1999, 4 : 69-77.Lien PubMed

Zou WP, Foussat A, Capitant C, Durand-Gasselin I, Bouchet L, Galanaud P, Levy Y, Emilie D.Acute activation of CD8 (+) T-Lymphocytes in Interleukine-2 – Treated HIV-Infected Patients.
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 1999, 22 (1) : 31-38.Lien PubMed

Zou W, Foussat A, Capitant C, Durand-Gasselin I, Bouchet L, Galanaud P, Levy Y, Emilie D.Acute upregulation of CCR-5 expression by CD4+ T lymphocytes in HIV-infected patients treated with interleukin-2. ANRS 048 IL-2 Study Group.
AIDS 1999, 13(4) : 455-463.

Aboulker JP.Drug-resistant Genotyping in HIV-1 Therapy. The Lancet, 1999, 354 ( : 1120) (Lettre).Lien PubMed